473 related articles for article (PubMed ID: 26044126)
1. Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease.
Munoz-Garrido P; Marin JJ; Perugorria MJ; Urribarri AD; Erice O; Sáez E; Úriz M; Sarvide S; Portu A; Concepcion AR; Romero MR; Monte MJ; Santos-Laso Á; Hijona E; Jimenez-Agüero R; Marzioni M; Beuers U; Masyuk TV; LaRusso NF; Prieto J; Bujanda L; Drenth JP; Banales JM
J Hepatol; 2015 Oct; 63(4):952-61. PubMed ID: 26044126
[TBL] [Abstract][Full Text] [Related]
2. Synthetic Conjugates of Ursodeoxycholic Acid Inhibit Cystogenesis in Experimental Models of Polycystic Liver Disease.
Caballero-Camino FJ; Rivilla I; Herraez E; Briz O; Santos-Laso A; Izquierdo-Sanchez L; Lee-Law PY; Rodrigues PM; Munoz-Garrido P; Jin S; Peixoto E; Richard S; Gradilone SA; Perugorria MJ; Esteller M; Bujanda L; Marin JJG; Banales JM; Cossío FP
Hepatology; 2021 Jan; 73(1):186-203. PubMed ID: 32145077
[TBL] [Abstract][Full Text] [Related]
3. Bile Acids in Polycystic Liver Diseases: Triggers of Disease Progression and Potential Solution for Treatment.
Perugorria MJ; Labiano I; Esparza-Baquer A; Marzioni M; Marin JJ; Bujanda L; Banales JM
Dig Dis; 2017; 35(3):275-281. PubMed ID: 28249268
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of NAE-dependent protein hyper-NEDDylation in cystic cholangiocytes halts cystogenesis in experimental models of polycystic liver disease.
Lee-Law PY; Olaizola P; Caballero-Camino FJ; Izquierdo-Sanchez L; Rodrigues PM; Perugorria MJ; Azkargorta M; Elortza F; Martinez-Chantar ML; Aspichueta P; Marzioni M; Bujanda L; Drenth JPH; Banales JM
United European Gastroenterol J; 2021 Sep; 9(7):848-859. PubMed ID: 34310849
[TBL] [Abstract][Full Text] [Related]
5. Targeting UBC9-mediated protein hyper-SUMOylation in cystic cholangiocytes halts polycystic liver disease in experimental models.
Lee-Law PY; Olaizola P; Caballero-Camino FJ; Izquierdo-Sanchez L; Rodrigues PM; Santos-Laso A; Azkargorta M; Elortza F; Martinez-Chantar ML; Perugorria MJ; Aspichueta P; Marzioni M; LaRusso NF; Bujanda L; Drenth JPH; Banales JM
J Hepatol; 2021 Feb; 74(2):394-406. PubMed ID: 32950589
[TBL] [Abstract][Full Text] [Related]
6. Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate.
Masyuk TV; Masyuk AI; Torres VE; Harris PC; Larusso NF
Gastroenterology; 2007 Mar; 132(3):1104-16. PubMed ID: 17383431
[TBL] [Abstract][Full Text] [Related]
7. Cholangiocyte autophagy contributes to hepatic cystogenesis in polycystic liver disease and represents a potential therapeutic target.
Masyuk AI; Masyuk TV; Lorenzo Pisarello MJ; Ding JF; Loarca L; Huang BQ; LaRusso NF
Hepatology; 2018 Mar; 67(3):1088-1108. PubMed ID: 29023824
[TBL] [Abstract][Full Text] [Related]
8. Ursodeoxycholate and tauroursodeoxycholate inhibit cholangiocyte growth and secretion of BDL rats through activation of PKC alpha.
Alpini G; Baiocchi L; Glaser S; Ueno Y; Marzioni M; Francis H; Phinizy JL; Angelico M; Lesage G
Hepatology; 2002 May; 35(5):1041-52. PubMed ID: 11981754
[TBL] [Abstract][Full Text] [Related]
9. HDAC6 is overexpressed in cystic cholangiocytes and its inhibition reduces cystogenesis.
Gradilone SA; Habringer S; Masyuk TV; Howard BN; Masyuk AI; Larusso NF
Am J Pathol; 2014 Mar; 184(3):600-8. PubMed ID: 24434010
[TBL] [Abstract][Full Text] [Related]
10. Proteostasis disturbances and endoplasmic reticulum stress contribute to polycystic liver disease: New therapeutic targets.
Santos-Laso A; Izquierdo-Sanchez L; Rodrigues PM; Huang BQ; Azkargorta M; Lapitz A; Munoz-Garrido P; Arbelaiz A; Caballero-Camino FJ; Fernández-Barrena MG; Jimenez-Agüero R; Argemi J; Aragon T; Elortza F; Marzioni M; Drenth JPH; LaRusso NF; Bujanda L; Perugorria MJ; Banales JM
Liver Int; 2020 Jul; 40(7):1670-1685. PubMed ID: 32378324
[TBL] [Abstract][Full Text] [Related]
11. The cAMP effectors Epac and protein kinase a (PKA) are involved in the hepatic cystogenesis of an animal model of autosomal recessive polycystic kidney disease (ARPKD).
Banales JM; Masyuk TV; Gradilone SA; Masyuk AI; Medina JF; LaRusso NF
Hepatology; 2009 Jan; 49(1):160-74. PubMed ID: 19065671
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Cdc25A suppresses hepato-renal cystogenesis in rodent models of polycystic kidney and liver disease.
Masyuk TV; Radtke BN; Stroope AJ; Banales JM; Masyuk AI; Gradilone SA; Gajdos GB; Chandok N; Bakeberg JL; Ward CJ; Ritman EL; Kiyokawa H; LaRusso NF
Gastroenterology; 2012 Mar; 142(3):622-633.e4. PubMed ID: 22155366
[TBL] [Abstract][Full Text] [Related]
13. Combination of a Histone Deacetylase 6 Inhibitor and a Somatostatin Receptor Agonist Synergistically Reduces Hepatorenal Cystogenesis in an Animal Model of Polycystic Liver Disease.
Lorenzo Pisarello M; Masyuk TV; Gradilone SA; Masyuk AI; Ding JF; Lee PY; LaRusso NF
Am J Pathol; 2018 Apr; 188(4):981-994. PubMed ID: 29366679
[TBL] [Abstract][Full Text] [Related]
14. Long-term effect of treating pregnant rats with ursodeoxycholic acid on the congenital impairment of bile secretion induced in the pups by maternal cholestasis.
Macias RI; Serrano MA; Monte MJ; Jimenez S; Hernandez B; Marin JJ
J Pharmacol Exp Ther; 2005 Feb; 312(2):751-8. PubMed ID: 15452192
[TBL] [Abstract][Full Text] [Related]
15. Ursodeoxycholic acid stimulates cholangiocyte fluid secretion in mice via CFTR-dependent ATP secretion.
Fiorotto R; Spirlì C; Fabris L; Cadamuro M; Okolicsanyi L; Strazzabosco M
Gastroenterology; 2007 Nov; 133(5):1603-13. PubMed ID: 17983806
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of metalloprotease hyperactivity in cystic cholangiocytes halts the development of polycystic liver diseases.
Urribarri AD; Munoz-Garrido P; Perugorria MJ; Erice O; Merino-Azpitarte M; Arbelaiz A; Lozano E; Hijona E; Jiménez-Agüero R; Fernandez-Barrena MG; Jimeno JP; Marzioni M; Marin JJ; Masyuk TV; LaRusso NF; Prieto J; Bujanda L; Banales JM
Gut; 2014 Oct; 63(10):1658-67. PubMed ID: 24436140
[TBL] [Abstract][Full Text] [Related]
17. Ursodeoxycholic Acid Ameliorates Intrahepatic Cholestasis Independent of Biliary Bicarbonate Secretion in Vil2
Hatano R; Kawaguchi K; Togashi F; Sugata M; Masuda S; Asano S
Biol Pharm Bull; 2017; 40(1):34-42. PubMed ID: 28049946
[TBL] [Abstract][Full Text] [Related]
18. Ursodeoxycholic acid in advanced polycystic liver disease: A phase 2 multicenter randomized controlled trial.
D'Agnolo HM; Kievit W; Takkenberg RB; Riaño I; Bujanda L; Neijenhuis MK; Brunenberg EJ; Beuers U; Banales JM; Drenth JP
J Hepatol; 2016 Sep; 65(3):601-7. PubMed ID: 27212247
[TBL] [Abstract][Full Text] [Related]
19. TGR5 contributes to hepatic cystogenesis in rodents with polycystic liver diseases through cyclic adenosine monophosphate/Gαs signaling.
Masyuk TV; Masyuk AI; Lorenzo Pisarello M; Howard BN; Huang BQ; Lee PY; Fung X; Sergienko E; Ardecky RJ; Chung TDY; Pinkerton AB; LaRusso NF
Hepatology; 2017 Oct; 66(4):1197-1218. PubMed ID: 28543567
[TBL] [Abstract][Full Text] [Related]
20. Combination of retinoic acid and ursodeoxycholic acid attenuates liver injury in bile duct-ligated rats and human hepatic cells.
He H; Mennone A; Boyer JL; Cai SY
Hepatology; 2011 Feb; 53(2):548-57. PubMed ID: 21274875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
